Sanofi exploring deal to buy Mirati Therapeutics, Bloomberg says

Sanofi (SNY) has been studying a potential acquisition of Mirati Therapeutics (MRTX), which is in the process of rolling out its first product, Krazati, which is used as a second-line treatment for a type of lung cancer, reported Bloomberg’s Michelle Davis, Dinesh Nair and Albertina Torsoli, citing sources. Deliberations are ongoing and Mirati could also attract interest from other suitors, the sources said. A spokesperson for Mirati said that it doesn’t comment on market rumors or speculation, which a representative for Sanofi also said it doesn’t comment on market rumors, the report noted. In afternoon trading following Bloomberg’s report, shares of Mirati have jumped about 17% to $50.29.